Glycogen synthase kinase 3 beta (GSK-3β) was one of the first kinases identified and studied, initially for its role in the regulation of glycogen synthesis. Over the past decade, interest in GSK-3β has grown far beyond glycogen metabolism, and this is due in large measure to the critical role that GSK-3β plays in the regulation of many other cellular processes, particularly cell proliferation and apoptosis. GSK-3β has been shown to regulate the proteolysis and sub-cellular compartmentalization of a number of proteins directly involved in the regulation of cell cycling, proliferation, differentiation and apoptosis. GSK-3β also regulates the degradation of proteins that regulate gene expression and thus affects a variety of important cell functions. Specifically, GSK-3β controls the degradation of β- catenin, the main effector of Wnt that regulates haematopoiesis and stem cell function. In this case GSK-3β is a negative regulator of Wnt. In contrast, GSK-3β positively regulates NF-κB, another important biochemical pathway also involved in the regulation of multiple aspects of normal and aberrant haematopoiesis. GSK-3β regulates degradation of IκB, a central inhibitor of NF-κB. In this way, GSK-3β acts to control the resistance of leukaemic cells to chemotherapy through the modulation of NF-κB, a critical factor in maintaining leukaemic cell growth. In addition, GSK-3β regulates the pro-inflammatory activity of NF-κB. As GSK-3β is a pleiotropic regulator, inhibitors may increase the range of novel anti-leukaemic and anti-inflammatory drugs that control immune response.
Keywords: Haematopoiesis, angiogenesis, leukaemogenesis, β-catenin, NF-κB, Wnt, haematopoietic stem cell, GSK-3β inhibition
Evaluation of Polygonum bistorta for Anticancer Potential Using Selected Cancer Cell Lines
Medicinal Chemistry The Transcription Factor ETS-1: Its Role in Tumour Development and Strategies for its Inhibition
Mini-Reviews in Medicinal Chemistry Src Family Kinases as Potential Therapeutic Targets for Malignancies and Immunological Disorders
Current Medicinal Chemistry OPLS-DA as a Suitable Method for Selecting a Set of Gene Transcripts Discriminating RAS- and PTPN11-Mutated Cells in Acute Lymphoblastic Leukaemia
Combinatorial Chemistry & High Throughput Screening The Use of Temozolomide for the Treatment of Malignant Tumors: Clinical Evidence and Molecular Mechanisms of Action
Recent Patents on Anti-Cancer Drug Discovery Cell Type Specific Redox Status is Responsible for Diverse Electromagnetic Field Effects
Current Medicinal Chemistry New Opportunities to Treat the T315I-Bcr-Abl Mutant in Chronic Myeloid Leukaemia: Tyrosine Kinase Inhibitors and Molecules that Act by Alternative Mechanisms
Current Medicinal Chemistry The use of nanocarriers in acute myeloid leukaemia therapy: challenges and current status.
Current Pharmaceutical Biotechnology Biological Activity In Vitro of Side-Chain Modified Analogues of Calcitriol
Current Pharmaceutical Design The Culture-Repopulating Ability Assays and Incubation in Low Oxygen: A Simple Way to Test Drugs on Leukaemia Stem or Progenitor Cells
Current Pharmaceutical Design Medical and Dental Implications of Down Syndrome: A Review Part 1: General and Craniofacial Characteristic
Applied Clinical Research, Clinical Trials and Regulatory Affairs Randomised Trials of Graft Versus Host Disease Prophylaxis in Haemopoietic Stem Cell Transplantation
Reviews on Recent Clinical Trials The Formulation of Lipid-Based Nanotechnologies for the Delivery of Fixed Dose Anticancer Drug Combinations
Current Drug Delivery Effects of Bioactive Compounds from Carrots (Daucus carota L.), Polyacetylenes, Beta-Carotene and Lutein on Human Lymphoid Leukaemia Cells
Anti-Cancer Agents in Medicinal Chemistry Protein Kinase CK2 Inhibitors: Emerging Anticancer Therapeutic Agents?
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Evaluation of 2-Substituted Fendiline Analogues as Antileukemics
Letters in Drug Design & Discovery Down-Regulation of Notch1 Expression is Involved in HL-60 Cell Growth Inhibition Induced by 4-Hydroxynonenal, a Product of Lipid Peroxidation
Medicinal Chemistry Machine Learning for Childhood Acute Lymphoblastic Leukaemia Gene Expression Data Analysis: A Review
Current Bioinformatics Synthesis of Cis-Fused Pyran Indolocarbazole Derivatives that Inhibit FLT3 Kinase and the DNA Damage Kinase, Checkpoint Kinase 1
Anti-Cancer Agents in Medicinal Chemistry Treatment of Relapsed Acute Myeloid Leukaemia
Reviews on Recent Clinical Trials